News

Prince who’s one of the most well-known addiction recovery and mental health advocates is one of several super-successful entrepreneurs featured in the book. Prince talks about the art of relationship building while being mindful of your mental health even at the height of success. He should know coming up on 15 years sober in July…

Partnerships have become crucial in helping people transition out of correction facilities with SUD treatment. For example, substance use disorder provider Groups Recover Together has partnered with several state correctional departments, including Indiana and Maine’s department of corrections (DOC), to provide transitional care and reentry services for individuals transitioning out of incarceration.

Bridge Therapeutics, today said that the MAT Act removes the outdated registration requirements on buprenorphine, making it possible for providers nationwide to prescribe it as they would any other controlled medication. Buprenorphine is a partial agonist or partial-acting opioid that treats addiction and chronic pain more safely than full-agonist opioids like morphine, oxycodone and fentanyl.

Treatment for opioid use disorder is limited by there not being enough people that offer medications for opioid use disorder,” said Brian Hurley, MD, MBA, president-elect of the American Society of Addiction Medicine (ASAM). “Removal of the X waiver opens up the capability of prescribing to a much broader group of clinicians.

What happens when a patient who is prescribed buprenorphine undergoes surgery? Experts say they should continue the medication, predominantly prescribed for opioid use disorder, throughout the entire perioperative period. It doesn’t need to be stopped, Lynn Kohan, MD, the medical director of the Pain Management Center told Pain Medicine News.

Bridge Therapeutics is delighted to announce that it achieved a Bronze Award on the Pepperdine Graziadio Business School’s fifth annual Most Fundable Companies® List. Bridge Therapeutics competed against over 4,000 of early-stage US companies to be named one of 16 finalists.

Lynn Fosse, Senior Editor of CEOCFO Magazine sits down with Tim Peara, President of Bridge Therapeutics to discuss commercialization and development of its opioid addiction and chronic pain drugs.

New York, New York – August 29, 2022:  Bridge Therapeutics, a developmental stage pharmaceutical company, today reported continued progress towards Phase 3 FDA approval of BT 219, a patented combination of Buprenorphine and Naloxone for Opioid Use Disorder (OUD). Simultaneously, Bridge reported that Darren Prince, an internationally recognized speaker and advisor on matters of addiction and mental health recovery…

Bridge reported that Darren Prince, an internationally recognized speaker and advisor on matters of addiction and mental health recovery has joined Bridge’s commercial advisory board. He abused opioids for more than 20 years before breaking his addiction, and then went on to help many other people, in and out of the entertainment industry, struggling with opiate…

Bridge Therapeutics announced today that they were selected as one of the Top 100 startups to compete and participate in the 9th Annual Startup of the Year Summit. “The Startup of the Year competition is a great way to showcase our innovative approach to treating opioid addiction and chronic pain,” says Dr. Greg Sullivan, founder and Chief Science Officer at Bridge Therapeutics.